zidovudine + lamivudine + abacavir + efavirenz

This antiretroviral combination, specifically zidovudine + lamivudine + abacavir + efavirenz, was the standardized Highly Active Antiretroviral Therapy (HAART) regimen utilized in the ANRS 112 INTERPRIM clinical trial. Sponsored by the French National Agency for Research on AIDS and Viral Hepatitis (ANRS), the trial investigated therapeutic strategies for patients with acute primary HIV infection. The regimen combines three nucleoside reverse transcriptase inhibitors (NRTIs)—zidovudine, lamivudine, and abacavir—with one non-nucleoside reverse transcriptase inhibitor (NNRTI), efavirenz. This potent combination targets the HIV-1 reverse transcriptase enzyme through both orthosteric (competitive) and allosteric (non-competitive) inhibition, effectively halting viral DNA synthesis. The INTERPRIM study evaluated the efficacy of this regimen when administered continuously versus intermittently, and also explored the addition of peginterferon alfa-2b to the intermittent schedule, aiming to optimize long-term viral suppression and immune recovery following early infection.

Other names

HAARTHighly Active Antiretroviral TherapyANRS 112 regimenANRS112 regimenANRS-112 regimenINTERPRIM regimen